MA68845A1 - Anticorps se liant à l'interleukine 13 et méthodes d'utilisation - Google Patents

Anticorps se liant à l'interleukine 13 et méthodes d'utilisation

Info

Publication number
MA68845A1
MA68845A1 MA68845A MA68845A MA68845A1 MA 68845 A1 MA68845 A1 MA 68845A1 MA 68845 A MA68845 A MA 68845A MA 68845 A MA68845 A MA 68845A MA 68845 A1 MA68845 A1 MA 68845A1
Authority
MA
Morocco
Prior art keywords
methods
interleukin
present
antibodies
aspects
Prior art date
Application number
MA68845A
Other languages
English (en)
Inventor
Peter HARWIN
Tomas KISELAK
Hussam H. Shaheen
Kenneth Evan Thompson
Original Assignee
Apogee Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogee Therapeutics, Inc. filed Critical Apogee Therapeutics, Inc.
Publication of MA68845A1 publication Critical patent/MA68845A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouveaux anticorps améliorés qui se lient à l'interleukine 13 (IL-13) et leurs méthodes d'utilisation. Dans certains aspects, la présente invention concerne des méthodes d'inhibition de l'activité biologique de l'IL-13. Dans certains aspects, la présente invention concerne des compositions pharmaceutiques comprenant les anticorps anti-IL-13. Dans certains aspects, les anticorps et les méthodes de la présente invention sont utilisés pour le traitement d'une maladie ou d'un trouble inflammatoire associé à des niveaux élevés d'IL-13 et/ou d'IgE.
MA68845A 2022-06-17 2023-06-16 Anticorps se liant à l'interleukine 13 et méthodes d'utilisation MA68845A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263353367P 2022-06-17 2022-06-17
US202363462822P 2023-04-28 2023-04-28
US202363469167P 2023-05-26 2023-05-26
PCT/US2023/068621 WO2023245187A2 (fr) 2022-06-17 2023-06-16 Anticorps se liant à l'interleukine 13 et méthodes d'utilisation

Publications (1)

Publication Number Publication Date
MA68845A1 true MA68845A1 (fr) 2025-11-28

Family

ID=89192087

Family Applications (1)

Application Number Title Priority Date Filing Date
MA68845A MA68845A1 (fr) 2022-06-17 2023-06-16 Anticorps se liant à l'interleukine 13 et méthodes d'utilisation

Country Status (19)

Country Link
US (2) US12358979B2 (fr)
EP (1) EP4540284A2 (fr)
JP (1) JP2025522482A (fr)
KR (1) KR20250025381A (fr)
CN (1) CN119730870A (fr)
AU (1) AU2023293289A1 (fr)
CA (1) CA3252634A1 (fr)
CL (1) CL2024003832A1 (fr)
CO (1) CO2025000282A2 (fr)
CR (1) CR20250009A (fr)
CU (2) CU20250005A7 (fr)
DO (1) DOP2024000265A (fr)
IL (1) IL317083A (fr)
JO (1) JOP20240279A1 (fr)
MA (1) MA68845A1 (fr)
MX (1) MX2024015659A (fr)
PE (1) PE20251639A1 (fr)
TW (1) TW202409094A (fr)
WO (1) WO2023245187A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4540284A2 (fr) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
WO2025128984A1 (fr) 2023-12-14 2025-06-19 Dermira, Inc. Anticorps il-13 pour le traitement de la rhinosinusite chronique avec des polypes nasaux
WO2025128990A1 (fr) 2023-12-14 2025-06-19 Dermira, Inc. Anticorps ciblant l'il-13 pour traiter la rhinite allergique apériodique
WO2025147575A1 (fr) * 2024-01-06 2025-07-10 Generate Biomedicines, Inc. Anticorps dirigés contre l'il-13 et leurs méthodes d'utilisation
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
WO2025264960A1 (fr) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Anticorps qui se lient à il -13 et anticorps qui se lient à ox40l
WO2026080829A1 (fr) 2024-10-10 2026-04-16 Apogee Therapeutics, Inc. Méthodes d'administration d'anticorps qui se lient à l'interleukine 13
WO2026085419A2 (fr) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Anticorps qui se lient à il-13 en combinaison avec de l'hyaluronidase ou un variant de celle-ci
WO2026085415A1 (fr) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Anticorps se liant à il-13 et anticorps se liant à tslp en combinaison avec de l'hyaluronidase ou un variant de celle-ci
CN119684453A (zh) * 2024-12-19 2025-03-25 江苏荃信生物医药股份有限公司 一种人il-13抗体、elisa试剂盒及其检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020050629A1 (fr) * 2018-09-04 2020-03-12 한국생산기술연구원 Matériau adhésif et son utilisation
WO2020182202A1 (fr) * 2019-03-13 2020-09-17 中兴通讯股份有限公司 Procédé de détection cohérente et récepteur cohérent
WO2020210216A1 (fr) * 2019-04-08 2020-10-15 SmileDirectClub LLC Systèmes et procédés de réglage de cisaillement d'un outil de coupe d'aligneur dentaire

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
WO2008140455A1 (fr) 2007-05-15 2008-11-20 Tanox, Inc. Traitement de la fibrose induite par radiation et chimiothérapie à l'aide de nouveaux anticorps monoclonaux anti-il-13
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
RU2578468C2 (ru) * 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
ES2936387T3 (es) 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
CN107099581B (zh) 2012-03-27 2021-07-13 弗·哈夫曼-拉罗切有限公司 预测、诊断和治疗特发性肺纤维化的方法
JP2016522168A (ja) 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
AR098155A1 (es) 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
CA2937387A1 (fr) 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur peripherique de l'activation de l'il-13 dans des poumons asthmatiques
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
WO2016073791A1 (fr) 2014-11-05 2016-05-12 Genentech, Inc. Procédés de production de protéines à deux chaînes dans des bactéries
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
WO2017011773A2 (fr) 2015-07-15 2017-01-19 Modernatx, Inc. Acides nucléiques à codons optimisés codant des anticorps
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
CA3020633A1 (fr) 2016-04-13 2017-10-19 Sanofi Proteines de liaison trispecifiques et/ou trivalentes
US20170298119A1 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
EP3448874A4 (fr) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
PT3528838T (pt) 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
JP6995127B2 (ja) 2017-02-10 2022-02-04 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体、その組成物、及びその使用
MA49279A (fr) 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
WO2018220216A1 (fr) * 2017-06-01 2018-12-06 Universität Stuttgart Hétérodimérisation de domaines ig
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
CN119291194A (zh) 2018-01-12 2025-01-10 建新公司 用于定量多肽的方法
CA3103374A1 (fr) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions et procedes d'administration d'anticorps
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
JP7784898B2 (ja) 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法
AU2020323901A1 (en) * 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
WO2021058711A2 (fr) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison à un antigène
MX2022007035A (es) 2019-12-09 2022-06-23 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
AU2021350156A1 (en) 2020-09-25 2023-06-08 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CA3199095A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Molecules de liaison a cd19 et utilisations associees
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
US20240101675A1 (en) 2021-01-21 2024-03-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
AU2022345969A1 (en) 2021-09-15 2024-03-07 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
US20250352644A1 (en) 2022-05-05 2025-11-20 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
EP4540284A2 (fr) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
AU2024262173A1 (en) 2023-04-28 2025-09-04 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 13

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020050629A1 (fr) * 2018-09-04 2020-03-12 한국생산기술연구원 Matériau adhésif et son utilisation
WO2020182202A1 (fr) * 2019-03-13 2020-09-17 中兴通讯股份有限公司 Procédé de détection cohérente et récepteur cohérent
WO2020210216A1 (fr) * 2019-04-08 2020-10-15 SmileDirectClub LLC Systèmes et procédés de réglage de cisaillement d'un outil de coupe d'aligneur dentaire

Also Published As

Publication number Publication date
PE20251639A1 (es) 2025-06-24
DOP2024000265A (es) 2025-02-28
CU20250005A7 (es) 2025-11-05
WO2023245187A3 (fr) 2024-07-18
US20250368733A1 (en) 2025-12-04
CU20240040A7 (es) 2025-07-09
US12358979B2 (en) 2025-07-15
EP4540284A2 (fr) 2025-04-23
KR20250025381A (ko) 2025-02-21
CN119730870A (zh) 2025-03-28
CR20250009A (es) 2025-05-07
JP2025522482A (ja) 2025-07-15
TW202409094A (zh) 2024-03-01
CA3252634A1 (fr) 2023-12-21
CO2025000282A2 (es) 2025-04-07
JOP20240279A1 (ar) 2024-12-17
US20250129150A1 (en) 2025-04-24
CL2024003832A1 (es) 2025-02-14
MX2024015659A (es) 2025-03-07
IL317083A (en) 2025-01-01
WO2023245187A2 (fr) 2023-12-21
AU2023293289A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
MA68845A1 (fr) Anticorps se liant à l'interleukine 13 et méthodes d'utilisation
Luque-Campos et al. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response
Molnar et al. Cytokines and chemokines involved in osteoarthritis pathogenesis
Hoge et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling
Torossian et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications
Chen et al. Th17 cells and Tregs: unlikely allies
MX2025009655A (es) Anticuerpos que se unen al receptor alfa de interleuquina 4 y metodos de uso
US10947288B2 (en) Targeting of human interferon antagonists
Adamopoulos et al. IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis
Polese et al. Innate lymphocytes in psoriasis
Pollard et al. Interferon-γ and systemic autoimmunity
Stott et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation
Ding et al. Silencing IFN-γ binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity
JOP20230234A1 (ar) أجسام مضادة لـ il-2r مؤازرة وطرق استخدامها
Kalechman et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels
Walrath et al. IFN-γ and IL-17A regulate intestinal crypt production of CXCL10 in the healthy and inflamed colon
Stein et al. Leukocyte-derived interleukin-10 aggravates postoperative ileus
ATE435239T1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
MX2025012892A (es) Anticuerpos que se unen a ox40l y metodos de uso
MX2025012790A (es) Metodos de administracion de anticuerpos que se unen a la interleuquina 13
Bouazzaoui et al. Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
Nechanitzky et al. Cholinergic control of Th17 cell pathogenicity in experimental autoimmune encephalomyelitis
Carrión et al. Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and-23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: immunomodulation by vasoactive intestinal peptide